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THICK AS THIEVES? BIG PHARMA WIELDS ITS POWER 
WITH THE HELP OF GOVERNMENT REGULATION† 
Leslie E. Sekerka∗ 
Lauren Benishek∗∗ 
INTRODUCTION 
Americans are barraged by an endless flow of ads that claim to remedy 
medical maladies with prescribed drugs. The commercials depict productive 
and happy lives, with suggestive associations that human flourishing can be 
achieved via pharmaceutical intervention. The appeals are accompanied by an 
exhaustive inventory of potentially negative life-altering side effects. As ads 
end with this depiction of relational bliss through drug use, viewers hear a fast-
paced listing of monotone non-segmented disclaimers, which can range from 
modest impacts (e.g., slight weight gain) to very serious implications (e.g., 
suicidal ideations). Research suggests that hearing about the risks of use may 
increase consumers’ trust in the advertising.1 Sufferers may also conclude that 
stronger means better (i.e., helping them more effectively manage their 
condition).2 Patients may prefer a name-brand drug because the medicine may 
have a higher perceived quality due to advertising and promotional activities.3 
American consumers are enculturated to reinforce their desire for convenience 
and accessibility, while also wanting their pains to go away. Moreover, they 
 
 † Portions of this article originally appeared in: Leslie Sekerka, Debra Comer & Lauren Benishek, The 
Inordinate Power of Big Pharma, in BUSINESS ETHICS: BEST PRACTICES FOR DESIGNING AND MANAGING 
ETHICAL ORGANIZATIONS 355 (Denis Collins ed., 2018). 
 ∗ Leslie E. Sekerka, PhD, is a Professor of Management at Menlo College. Her interest in adult moral 
development stems from working in industry, government, and academia. She connects with Silicon Valley 
business leaders to resolve emerging ethical issues and is known globally as a business ethics expert, providing 
workshops that advance employees’ moral competency. Dr. Sekerka is founding director of the Ethics in 
Action Center and an Academic Partner at Santa Clara University’s Markkula Center for Applied Ethics. 
 ∗∗ Lauren Benishek, PhD, is an Assistant Professor at John Hopkins University, School of Medicine’s 
Armstrong Institute for Patient Safety and Quality. She seeks to translate organizational science into practical 
applications that have large-scale impact. Dr. Benishek’s specialties and research interests coalesce on three 
major themes: (1) professional talent development, (2) safety and well-being, and (3) teamwork and unit 
dynamics. 
Special thanks to Debra Comer who contributed to the original case study, providing source material for 
this article. 
 1 Amanda L. Connors, Comment, Big Bad Pharma: An Ethical Analysis of Physician-Directed and 
Consumer-Directed Marketing Tactics, 73.1 ALB. L. REV. 243 (2009).  
 2 See also Joanne Kaufman, Think You’re Seeing More Drugs Ads on TV? You Are, and Here’s Why, 
N.Y. TIMES, Dec. 24, 2017, https://www.nytimes.com/2017/12/24/business/media/prescription-drugs-
advertising-tv.html.  
 3 Kathleen Iacocca, James Sawhill & Yao Zhao, Why Brand Drugs Priced Higher Than Generic 
Equivalents, 9 INT’L J. PHARM. & HEALTHCARE MKTG. 3 (2015). 
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expect to view ads that compel them to want novel products or new 
applications. When it comes to health, consumers tend to mitigate the risk of 
taking drugs.4 Cognitive dissonance fuels a process of rationalizing side effects 
as part of the cost of wellbeing.5  
Direct-to-consumer pharmaceutical advertising (DTCPA) refers to any 
promotional effort by a pharmaceutical company to present pharmaceutical 
drug information to the public in the lay media.6 Drug companies claim the ads 
are designed to educate patients, encourage doctor-patient dialogue, and move 
people to take more responsibility for their healthcare.7 Opponents suggest that 
this type of marketing tends to normalize obscure disorders, encourages people 
to believe they suffer from certain dysfunctions, and prompts framing 
uncommon diseases in a normal light.8 When pharmaceutical firms get U.S. 
Federal Drug Administration (FDA) approval for a new product, under the 
auspices of health communication, the government enables them to market the 
drug and create demand where none previously existed.  
  
 
 4 Ho-Young Ahn et al., Consumers’ Optimism Bias and Responses to Risk Disclosures in Direct-to-
Consumer (DTC) Prescription Drug Advertising: The Moderating Role of Subjective Health Literacy, 48 J. 
CONSUMER AFFAIRS 175 (2014). 
 5 Johanna Jarcho et al., The Neural Basis Rationalization: Cognitive Dissonance Reduction during 
Decision Making, SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE, no. 6.4, 2011, at 460-67. 
 6 Billion Dollar Pills, ECONOMIST (Jan. 25, 2007), https://www.economist.com/node/8585891 (in 
America, direct-to-consumer drug advertising has increased from spending of $1.1 billion in 1997 to $4.5 
billion in 2006); The Impact of Direct-to-Consumer Advertising, U.S. FOOD AND DRUG ADMIN., 
https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143562.htm (last visited Mar. 20, 2018). 
 7 Editorial, Turn the Volume Down on Drug Ads, N.Y. TIMES (Nov. 27, 2015), https://www.nytimes. 
com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html.  
 8 Michael Wilkes et al., Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and 
Implications, 2000 HEALTH AFF. 19(2) at 110, 112.; Martin Hirsch (2008). Side effects of corporate greed: 
Pharmaceutical companies need a dose of corporate social responsibility. 9 MINN. J. L., SCI. & TECH. 607 
(2008). 
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Table 1. Top U.S. Drug Advertisement Expenditures (2016)9 
 
Drug/Maker Advertisement 
(in USD millions) 
Purpose 
Humira/AbbVie  $439 Anti-inflammatory 




$296 Blood thinner 
Xeljanz/Pfizer $258 Anti-inflammatory 
Opdivo/Bristol-Myers 
Squibb 
$168 Cancer treatment  
Chantix/Pfizer $151 Smoking cessation 
Cialis/Lilly $150 Erectile dysfunction 
Trulicity/Lilly $142 Increase glucose 
(diabetes) 
Prevnar/Pfizer $142 Pneumonia vaccine 
The pharmaceutical industry spends hundreds of millions of dollars 
annually to market its products. Direct-to-consumer prescription ads are the 
second-fastest growing ad category, competing with other top marketers 
stemming from automotive, fast food, insurance, and cable/wireless 
providers.10,11 Ad spending for television by pharmaceutical companies has 
more than doubled in the last four years, representing a 65% increase in this 
genre since 2012. It is currently the seventh largest ad category in the U.S., 
 
 9 Jon Swallen, Drug Advertising Booms to $6.4 Billion, KANTAR (May 8, 2017, 4:00 PM), 
http://us.kantar.com/business/health/2017/drug-advertising-booms/. 
 10 Rachel Kornfield et al., Trends in Exposure to Televised Prescription Drug Advertising, 2003–2011, 
48 AM. J. PREVENTIVE MEDICINE 5 (May 2015). 
 11 Bruce Horovitz & Julie Appleby, Prescription drug costs are up; So are TV ads promoting them, 
USA TODAY (Mar. 16, 2017, 7:04 AM), https://www.usatoday.com/story/money/2017/03/16/prescription-
drug-costs-up-tv-ads/99203878/. 
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investing $6.4 billion in 2016.12 Table 1 offers examples of top U.S. drug 
advertisement expenditures in 2016.13 Yet, greater ad spending does not 
necessarily correlate with product effectiveness. One of the most advertised 
drugs in 2016, Jublia (a toe fungus treatment),14 costs about $600 a bottle but 
is reported to work in fewer than 20% of users.15  
In 2016, 80 prescription drug advertisements were televised every hour, 
totaling 1,920 drug ads directed at American viewers per day.16 Television 
networks—ABC, CBS, NBC—along with cable channels like CNN draw 
millions of dollars from pharmaceutical advertising, approximately 8% of their 
ad revenue.17 Given U.S. viewers watch about five hours of television daily,18 
many citizens are likely to spend more time listening to pharmaceutical 
advertisements than talking with their physician (typically 15 minutes per visit, 
four times a year).19,20,21  
All this advertising can increase the cost of prescription drugs.22 Ironically, 
these ads actually serve as tax deductions for pharmaceutical firms.23 
Legislation to eliminate this deduction is currently being debated in the U.S. 
Congress but powerful lobby groups backed by the industry are challenging 
 
 12 Jon Swallen, Drug Advertising Booms to $6.4 Billion, KANTAR (May 8, 2017, 4:00 PM), 
http://us.kantar.com/business/health/2017/drug-advertising-booms/. 
 13 Id. 
 14 Aimee Picchi, Drug ads: $5.2 billion annually—and rising, CBS NEWS: MONEYWATCH (Mar. 11, 
2016, 3:25 PM), https://www.cbsnews.com/news/drug-ads-5-2-billion-annually-and-rising/. 
 15 Treating Toenail Fungus, CONSUMER REPORTS (Jan. 7, 2016), https://www.consumerreports.org/ 
health/treating-toenail-fungus/. 
 16 Alix Spiegel, Selling Sickness: How Drug Ads Changed Healthcare, NPR (Oct. 13, 2009), 
http://www.npr.org/templates/story/story.php?storyId=113675737. 
 17 Horovitz, supra note 10. 
 18 John Koblin, How Much Do We Love TV? Let Us Count the Ways, N.Y. TIMES (June 30, 2016), 
https://www.nytimes.com/2016/07/01/business/media/nielsen-survey-media-viewing.html. 
 19 Carol Peckham, Medscape Physician Compensation Report 2016, MEDSCAPE (Apr. 1, 2016), 
http://www.medscape.com/features/slideshow/compensation/2016/public/overview?src=wnl_physrep_160401
_mscpedit&uac=232148CZ&impID=1045700&faf=1#page=26. 
 20 Tim Mackey & Bryan Liang, It’s Time to Shine the Light on Direct-to-Consumer Advertising, 13 
ANNALS FAMILY MEDICINE 82 (2015). 
 21 Niall McCarthy, Americans Visit Their Doctor 4 Times A Year. People In Japan Visit 13 Times A 
Year [infographic], FORBES (Sep. 4, 2014, 8:47 AM), https://www.forbes.com/sites/niallmccarthy/2014/09/04/ 
americans-visit-their-doctor-4-times-a-year-people-in-japan-visit-13-times-a-year-
infographic/#35107e87e347/. 
 22 Thomas Dibacco, Just say no to drug ads on TV, WASH. TIMES (Feb. 8, 2017), 
https://www.washingtontimes.com/news/2017/feb/8/drug-ads-on-tv-should-be-banned/. 
 23 Insideradio, Tax bill targets big pharma advertising deductions.  (March 13, 2018), http://www. 
insideradio.com/free/tax-bill-targets-big-pharma-advertising-deductions/article_5db46c5a-2685-11e8-bb4e-
1ba75015db76.html. 
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these reforms with tenacious veracity.24 To better understand the 
interconnections between the U.S. government and the pharmaceutical 
industry, it is important to explain the industry’s historical context. From there, 
issues can be discussed and ideas for systemic change considered. 
I. THE GENESIS OF BIG PHARMA 
To understand what drives these ads, it is necessary to examine the trillion-
dollar pharmaceutical industry known as Big Pharma. Big Pharma is the name 
ascribed to a consortium of the world’s largest drug companies. The term is 
applied to the vast and influential pharmaceutical industry and its trade group 
in the U.S., known as the Pharmaceutical Research and Manufacturers of 
America (PhRMA). Given the astronomical amount of money made in the 
global prescription drug business, the industry has inordinate power and 
influence over consumers’ lives. It is no surprise, then, that Big Pharma is the 
subject of heated debate amongst many stakeholder groups.25  
Drug companies like Merck, Eli Lilly, and Roche; and chemical firms like 
Bayer, ICI, Pfizer, and Sandoz, have been in business for more than 100 years, 
going back to a time when most medicines were sold without prescriptions and 
roughly half were provided by local druggists. The period between 1918 and 
1939 was marked by the discovery and modest production of penicillin and 
insulin.26 As demand for analgesics and antibiotics escalated during World 
War II, a government-supported international collaboration, including Merck, 
Pfizer, Squibb, and Lilly, sought to mass produce penicillin.27 The 
unprecedented success of this effort signaled a new direction for drug 
development involving collaboration between companies and the government, 
forecasting the advent of the modern pharma industry.  
The implementation of state healthcare systems in the post-war period 
created a more stable market for prescribing and reimbursement processes. For 
example, in 1957 the UK established a pricing scheme that enabled reasonable 
 
 24 Beth Bulick, Tax bill may target pharma’s DTC deduction, but ad industry’s ready to defend it, 
FIERCEPHARMA (Dec. 11, 2017, 8:06 AM), https://www.fiercepharma.com/marketing/tax-bill-may-look-to-
deny-pharma-advertising-deduction-but-ad-association-ready-to-defend. 
 25 See generally MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES: HOW THEY DECEIVE US 
AND WHAT TO DO ABOUT IT (Random House, reprt. ed. 2005). 
 26 David Taylor, The Pharmaceutical Industry and the Future of Drug Development, 41 
PHARMACEUTICALS IN THE ENVIRONMENT 1 (R. Hester & R. Harrison eds., 2015).  
 27 Discovery and Development of Penicillin, AM. CHEMICAL SOC. INT’L HISTORIC CHEMICAL 
LANDMARKS, https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html 
(last visited Apr. 13, 2018).  
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investment returns and incentivized commercial investment in the research and 
manufacture of new products.28 In the ensuing years, consumers benefited 
from the introduction of over-the-counter products like acetaminophen and 
ibuprofen, complemented by completely new classes of pharmaceuticals such 
as oral contraceptives, betablockers, ACE inhibitors, benzodiazepines, and a 
range of cancer treatments.29  
Between 1980–2000, drug development was largely in the hands of 
multinationals, prompting the creation of “blockbuster drugs.” These chemical 
compounds were designed to become consumer staples as treatments for 
common, chronic ailments. For example, the ulcer medication Tagamet 
quickly reached $1 billion in sales, followed by a succession of other 
blockbusters like Eli Lilly’s Prozac (the first serotonin reuptake inhibitor) and 
Astra’s Omeprazole (the first proton pump inhibitor). Pfizer’s cholesterol drug 
Lipitor became the best-selling drug of all time, with $125 billion in sales over 
15 years. Pharmaceuticals strategically promote products expected to become 
the most profitable. For example, in 2011 Boehringer Ingelheim spent $464 
million advertising its blood thinner Pradaxa. The investment appears to have 
paid off: the drug passed the $1 billion sales mark the following year.  
Today, prescription drugs are a massive market. Americans spent $325 
billion in 2015 (equating to 1.8% of GDP and 10% of total national health 
expenditures) on retail prescriptions alone (not including drugs administered 
directly by healthcare providers).30 Critics are concerned that pharmaceutical 
firms are driven more by financial self-interest than by their espoused values to 
serve society. Given today’s legal environment, this industry is expected to 
reach $5.7 trillion by 2026, representing a 5/5% growth rate per year (2017-
2026).31 Pharmaceuticals have an especially robust duty to society because 
they have the power to contribute to or deny the ability to live a healthy life.  
 
 28 Lesley Hannah & Jessica Phillips, Is the Current UK System of Pharmaceutical Price Regulation 
Working?, LEXOLOGY (Feb. 20, 2017), https://www.lexology.com/library/detail.aspx?g=4f3f95a6-a667-4d6d-
a113-09ec8a094cdd.  
 29 DAVID TAYLOR, The Pharmaceutical Industry and the Future of Drug Development, in 
PHARMACEUTICALS IN THE ENVIRONMENT (VOL. 41) (R. Hester & R. Harrison eds., 2015). 
 30 Peter Olson & Louise Sheiner, The Hutchins Center Explains: Prescription Drug Spending, 
BROOKINGS (Apr. 26, 2017), https://www.brookings.edu/blog/up-front/2017/04/26/the-hutchins-center-
explains-prescription-drug-spending/. 
 31 National Health Expenditure Projections 2017–2026: Forecast Summary, CTRS. FOR MEDICARE & 
MEDICAID SERVS. (2018), https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. 
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II. DIRECT-TO-CONSUMER PHARMACEUTICAL ADS 
Ventola’s research provides historical context for DTCPA practices 
today.32 The Division of Drug Marketing, Advertising, and Communications 
(DDMAC) within the FDA is responsible for DTCPA’s regulation.33 The FDA 
was given authority to approve pharmaceutical products for marketing in the 
U.S., as a result of the Federal Food, Drug, and Cosmetic Act, passed in 
1938.34 In 1962, the FDA was afforded statutory authority to regulate 
prescription drug labeling and advertising. Most recently, in 1969, the FDA 
stipulated that pharmaceutical ads must (1) not be false or misleading, (2) 
fairly represent a drugs risks and benefits, (3) include facts that are “material” 
to the product’s advertised uses, and (4) briefly summarize every risk 
described in the product’s labeling.35 During the 1980s, the political climate 
became more favorable to the pharmaceutical industry. Patients also became 
more active participants in their medical decision-making, interacting with 
their healthcare providers.  
With television introducing DTCPAs, the FDA had to consider new 
questions about how consumer drug advertising should be regulated.36 In 1983, 
the FDA imposed a voluntary moratorium, requesting that pharmaceutical 
firms sustain from DTCPA while the agency studied the issue.37 In 1985, the 
FDA published a notice in the Federal Register claiming regulatory 
jurisdiction over DTCPA, affirming that the prior standards of “fair balance” 
and “brief summary”, were sufficient to protect American consumers against 
deceptive or misleading claims.38 Including additional information was 
deemed costly and time prohibitive by pharmaceutical firms. As a result, ads 
ultimately ended up being largely geared to encourage help-seeking, rather 
than making direct product claims. Providing medical information to patients 
via DTCPA’s presumably empowers them to discuss these treatments with 
their providers. 
 
 32 C. Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 PHARMACY 
& THERAPEUTICS 669 (Oct. 2011). 
 33 Id.; see also Connors, supra at note 23. 
 34 William Boden & George Diamond, DTCA for PTCA – Crossing the Line in Consumer Health 
Education?, 358 NEW ENG. J. MED. 2197 (May 2008). 
 35 Id. 
 36 See Jeremy Greene & David Herzberg, HIDDEN in PLAIN SIGHT Marketing Prescription Drugs to 
Consumers in the Twentieth Century, 100 AM. J. PUB. HEALTH 793 (May 2010). 
 37 Id. 
 38 Id. 
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Twelve years later, after a hearing in 1995, the FDA issued a draft 
guidance (with final regulations in 1999), explaining that advertisers had to 
include only “major risks” and provide an “adequate provision” that would 
direct viewers elsewhere to access complete “brief summary” information 
elsewhere (via a toll-free number, a healthcare provider, website, etc.).39 In 
1997, advertising of prescription drugs and medical devices was legalized. The 
FDA further relaxed the regulations in 2004, eliminating complete prescribing 
information in print product claim ads and allowing the inclusion of a 
simplified brief summary instead.40 At this point, pharmaceutical companies 
only had to provide information on “major risks” and provide simplified 
language (i.e., easier for the average consumer to understand).41  
The FDA continues to regulate DTCPA, but critics say that now rules are 
too relaxed and inadequately enforced.42 Scholars writing for the New England 
Journal of Medicine suggest that DTCPA increases pharmaceutical sales by 
wielding a double-edged sword. The ads can simultaneously avert underuse, 
but also contribute to potential overuse.43 Serious concerns were expressed and 
DTCPAs received increased attention when some very heavily advertised 
drugs were suddenly removed from the market, after finding that they carried 
serious risks. In 2015, the American Medical Association (AMA) voted that 
the U.S. government should impose a ban on this practice. And yet, DTCPAs 
continue to appear with disturbing regularity. The U.S. and New Zealand 
remain the only two countries that permit these types of advertisements.44 It is 
therefore no coincidence that citizens of only two countries take an average of 
more than two prescription medications regularly: the U.S. and New Zealand.45  
The USFDA, the agency responsible for pharmaceutical regulation, has 
done little to address the AMA’s concern that these ads prompt consumers to 
seek inappropriate drugs and to believe that there is a pill for every ill, even for 
 
 39 Gregory Abel et al., Direct-to-Consumer Advertising in Oncology, 11 ONCOLOGIST 217 (2006). 
 40 Amy Shaw, Direct-to-Consumer Advertising (DTC) of Pharmaceuticals, PROQUEST (Mar. 2008), 
citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.549.4384&rep=rep1&type=pdf. 
 41 C. Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 PHARMACY 
& THERAPEUTICS 669 (Oct. 2011). 
 42 See Connors, supra at note 25. See also Donahue JM, Cervasco M, Rosenthal MB. A decade of 
direct-to-consumer advertising of prescription drugs. NEW ENG. J. MED. 2007; 357(7):673–81. 
 43 Id. 
 44 Direct-to-consumer Advertising Under Fire, WORLD HEALTH ORG., http://www.who.int/bulletin/ 
volumes/87/8/09-040809/en/ (last visited May 3, 2018). 
 45 U.S. Health Care from a Global Perspective, COMMONWEALTH FUND, http://www. 
commonwealthfund.org/publications/issue-briefs/2015/oct/us-health-care-from-a-global-perspective (last 
visited Mar. 26, 2018). 
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conditions effectively treated through diet and exercise.46 Marcia Angell, 
former editor-in-chief of The New England Journal of Medicine disputes 
pharmaceutical companies’ arguments that they need to boost profits to fund 
their research. She explains how these ads are “designed to convince people 
that they need pills… that happen to be more expensive” (i.e., typically those 
just entering the market).47 When consumers go to see their physician, their 
requests for specific medications they have seen advertised are likely to be 
honored. Doctors do not want to lose patients, and they need to move quickly. 
Given expectations to see greater numbers of patients, it may be easier and 
faster to write a prescription than to discuss alternatives. Consumers have also 
started to expect easy, passive medication-based solutions to health concerns, 
becoming less interested in discussing other options (e.g., diet, lifestyle 
changes) that may be less convenient, but better for their long-term health. 
Between 1999-2012 there were significant increases in adult prescription 
drugs: from 51% in 1999-2000 to 59% in 2011-2012. During the same time, 
the prevalence of polypharmacy (use of multiple drugs to treat a single 
ailment/condition) also increased from 8.2% to 15%.48  
One study showed that people who regard DTCPA positively or neutrally 
may be more vulnerable to ad messaging. Promotion-focused ads that highlight 
positive health outcomes are favorable to individualistic-oriented persons 
whereas prevention-focused ads that underscore negative health outcomes (of 
not taking a drug) are favored by interdependent-oriented persons.49 When an 
ad’s focus matches their personal orientation, viewers are more likely to 
conclude a causal connection between taking the pharmaceutical and achieving 
the desirable lifestyle depicted in the ad. Furthermore, another study noted that 
the motivation for taking a drug (i.e., to live a desirable lifestyle versus to 
avoid pain or negative outcomes) was predominant and repeatedly reinforced 
within ads while risk information was presented only once.50 Doctors are also 
influenced, led to prescribe name brand drugs, which may not be better than 
generic alternatives.  
 
 46 See Ventola, supra at note 29. 
 47 Interview: Marcia Angell, GPB: FRONTLINE (June 19, 2003), 
https://www.pbs.org/wgbh/pages/frontline/shows/other/interviews/angell.html. 
 48 Elizabeth Kantor et al., Trends in Prescription Drug Use among Adults in the United States from 
1999–2012, 314 JAMA 1818 (2015). 
 49 Nithima Sumpradit et al., “Give Me Happiness” or “Take Away My Pain”: Explaining consumer 
responses to prescription drug advertising, 2 COGENT BUS. & MGMT. 1 (2015). 
 50 N. Sumpradit et al., A Cross-Media Content Analysis of Motivational Themes In Direct-To-
Consumer Prescription Drug Advertising, 26(1) CLINICAL THERAPEUTICS 135 (2004). 
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In probing the contours of this issue, we must consider whether consumers 
experience the benefits defendants claim that DTCPAs provide. If, for 
instance, a consumer suffers a psychiatric or neurological illness that can 
impair their decision making capacity, they may be at risk of undue influence 
from these ads.51 Yet, one study found that 18% of the 50 drugs advertised 
most assiduously in the U.S. were medications used to treat these kinds of 
disorders.52  
One physician described how helpful conversations between patient and 
doctor, which pharmaceutical ads supposedly prompt, are not helpful when 
they hijack precious time in an already brief encounter.53 He explained that he 
wants to focus on what is most relevant and beneficial for his patients’ health, 
adding: “If I have to spend my time fending off marketing for a condition you 
don’t have or a drug that’s of no possible benefit to you, our time hasn’t been 
used productively.”54 The medical community has shared its belief that 
DTCPA creates an inappropriate demand for medications and/or a demand for 
inappropriate medications.55 
The Protecting Americans from Drug Marketing Act was introduced in 
2009, a bill designed to encourage companies to focus on developing new 
medicines, instead of developing marketing schemes. Legislation, which would 
amend the Internal Revenue Code (removing the tax deduction), is part of a 
growing trend to minimize the pervasiveness of DTCPA. Policymakers have 
asked for a three-year moratorium on advertising newly approved prescription 
drugs to consumers. Again, the AMA called for a ban on this form of 
promotion, with support from a variety of stakeholder groups. But efforts to 
push for a ban have stalled, given free-speech arguments made by the powerful 
drug lobby and assertions that such ads provide valuable information to 
patients about treatment options. Now moving to explore other aspects of the 
relationship between Big Pharma and the U.S. government, we can see how 
transactional reciprocity appears to fuel how legislation is cultivated and 
imposed. 
 
 51 Matthew Hollon, Direct-to-consumer marketing of prescription drugs: a current perspective for 
neurologists and psychiatrists, 18 CNS DRUGS 69 (2004). 
 52 Id. 
 53 John Schumann, Those TV Drug Ads Distract Us From The Medical Care We Need, NPR (Apr. 29, 
2017, 5:00 AM), https://www.npr.org/sections/health-shots/2017/04/29/525877472/those-tv-drug-ads-distract-
us-from-the-medical-care-we-need. 
 54 Id. 
 55 Id. at 1098 (quoting from Prescription Drug Advertising Direct to the Consumer, 88 PEDIATRICS 174, 
175 (1991)). 
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III. GOVERNMENT REGULATION 
Government regulation is designed to ensure that businesses serve the 
public good, not just a fiduciary duty to their shareholders. But it is debatable 
if, when, and how these regulatory efforts effectively serve the public. Looking 
back, the 1940s, known as the “antibiotic era,” prompted a robust period for 
the discovery and development of pharmaceutical products. This has since 
evolved into an expensive, time-consuming, cumbersome, and bureaucratic 
process.56 With the Thalidomide scandal in 1961, the medical community was 
shocked to learn that a drug being given to pregnant women caused serious 
birth defects. This prompted activists and stakeholder groups to take action, 
demanding a regulatory response.57 This particular event triggered a 
government reassessment of government controls. New regulations were 
imposed to require efficacy, purity, and safety—greatly increasing research 
and development (R&D) costs, particularly in the area of clinical testing. An 
unintended consequence was that these enhanced regulations were deemed as 
barriers to market entry, providing impetus to drive the pharmaceutical 
industry’s consolidation.58 
Today, the pharmaceutical industry contributes heavily to the FDA’s 
annual budget. Back in 1992, the Prescription Drug User Fee Act (PDUFA) 
passed, making it the law for pharmaceutical companies to pay the FDA to 
review their applications for drug approvals. In response to a lethargic and 
burdensome process, this law was supposed to enable the FDA to work more 
efficiently and effectively, having more resources to conduct rigorous and 
timely reviews. In return, pharmaceutical firms would be able to send their 
products through the regulatory pipeline faster, and patients would receive new 
and potentially life-saving drugs more quickly. While the intent seemed to 
serve the greater good, many argued that PDUFA put the FDA into the pockets 
of the drug industry.59 Avalere Health explored and reported how much 
pharma companies have actually paid the FDA through PDFUA, adding up the 
wide variety of fees collected for different types of applications (e.g., for each 
 
 56 S. Projan, Why is Big Pharma Getting Out of Antibacterial Drug Discovery?, 6(5) CURRENT OPINION 
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 57 Annas, George J., and Sherman Elias. “Thalidomide and the Titanic: Reconstructing the Technology 
Tragedies of the Twentieth Century.”Health Law and Ethics 89 (1999): 98–101. Retrieved from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508516/. 
 58 Taylor, D. (2015). The pharmaceutical industry and the future of drug development. Pharmaceuticals 
in the Environment, 1-33. DOI: 10.1039/9781782622345-00001 eISBN:978-1-78262-234-5. 
 59 Ramsey, L., & Friedman, L.F. (2016). The government agency in charge of approving drugs gets a 
surprising amount of money from the companies that make them. Business Insider, August, 17. Retrieved 
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prescription drug application with clinical data, the fee in 2016 was over $2 
million). This report found that since PDUFA was passed in 1992, pharma 
companies have contributed $7.67 billion to the federal agency’s coffers.60 
This creates a interconnectedness between the two entities: a marriage between 
Big Pharma and the government can potentially blur the intent of government 
regulation and the role that it plays in protecting citizens.  
Although interest groups have emerged to represent the rights of 
companies and patients alike (e.g., pharmaceutical manufacturers, 
governmental regulatory authorities, patent officers, academic and clinical 
researchers, attorneys, and political action committees [PACs]). With huge 
profits and a thousand paid lobbyists, Big Pharma often gains leverage in how 
legislation is crafted and/or abandoned. From 1998 to 2014, Big Pharma spent 
nearly $3 billion on lobbying, drowning out the voices of consumers and the 
interest groups that try to represent them.61 While some stakeholder-driven 
activist groups, like Patients for Affordable Drugs, work to represent the voice 
of constituents, a number of powerful groups that claim to represent patient 
advocacy are tainted by special interest biases. One study shows that nearly all 
patient advocacy groups are manipulated or captured by the drug industry; over 
80% of these groups take money from Big Pharma.62 
The Project on Government Oversight (POGO) reports that at least 39 of 
42 patient advocacy groups who participated in discussions with the FDA over 
agency review processes for prescription drugs received funding from 
pharmaceutical companies.63 Additionally, at least 15 advocacy groups have 
representatives of drug or biotechnology companies on their governing boards. 
Congress recently passed the 21st Century Cures Act in 2016, authorizing $6.3 
billion64 in federal funding and weakening the FDA’s approval process.65 Over 
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Retrieved from: http://avalere.com/expertise/life-sciences/insights/fda-has-received-7.67-billion-from-
manufactures-to-fund-drug-review. 
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1,400 lobbyists worked on the bill, which served as a major financial boon to 
the drug and medical device industries. While patient advocacy groups were 
engaged, many were not independent. For example, the National Health 
Council, a group that calls itself The United Patient Voice, has advocated 
before the FDA for faster drug approvals. Members of its board of directors 
include leaders from two of the main trade groups for the drug industry—
Pharmaceutical Research and Manufacturers of America (PhRMA), and 
Biotechnology Innovation Organization (BIO)—along with executives from 
drug companies Sanofi, Johnson & Johnson, and Alkermes. PhRMA gave the 
National Health Council $1.2 million in 2014; in all, 77% of its funding came 
from the pharmaceutical and biotech industries, according to POGO.66 The 
United Patient Voice Policy Action Team also has a PhMRA representative on 
it, along with an employee of Johnson & Johnson.67 
According to reports by nonprofit MapLight, drug companies poured more 
than $70 million into fighting California’s Proposition 61, intended to limit the 
prices state agencies pay for prescription drugs.68 The industry often backs 
legislators who favor their shareholder-driven approach. For example, Big 
PhRMA spent $7 million in 2016 for their “Go Boldly” ad campaign, giving 
millions to politicians who were up for election in both parties in dozens of 
states.69 The drug companies lavished more than $2 million on scores of 
groups representing patients with various diseases—many of them dealing with 
high drug costs. The trade group PhRMA is also known for hiring former 
government employees, who are connected to those in political office.70 Using 
these relationships to pursue industry goals, Big Pharma maintains a significant 
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advantage that can be used to override stakeholder interests. Such integrated 
forms of control contribute to the high cost and limited availability of certain 
drugs. U.S. citizens pay more than those of any other country for their 
pharmaceuticals.71 U.S. prices for major brand-name drugs spiked 127% 
between 2008-2014.72 This is in comparison with an 11% rise in a shopping 
cart of common household goods (according to Express Scripts, the largest 
U.S. manager of drug plans).73 Big Pharma often points to extensive 
development costs to justifying its pricing strategies. However, this 
explanation merits additional consideration. 
Aiming to improve American-owned businesses in global markets, 
Congress enacted a series of laws designed to speed up tax-supported research 
on new products. One of these laws, the Bayh-Dole Act of 1980,74 enabled 
universities and small businesses to patent and/or license any discoveries from 
their tax-funded medical research sponsored by the National Institutes of 
Health (NIH). Prior to this law, taxpayer-financed discoveries belonged to the 
public domain (i.e., new drugs were available to any company that wanted 
them). As the result of this legislation, universities that carried out NIH-
sponsored work could charge royalties, providing income for non-profit 
institutions. Legislation was also passed that allowed the NIH to enter into 
deals with drug companies, transferring NIH discoveries directly to industry.  
This wave of legislation provided a huge boost to the nascent 
biotechnology industry, thereby paving the way for a tremendous buildup of 
Big Pharma. Small biotech operations, many of them founded by university 
researchers, proliferated. Much of the burden for the initial phases of drug 
development shifted from Big Pharma to smaller firms. The smaller firms 
worked to secure deals with Big Pharma, who would then take over the 
marketing of these discoveries and some level of ownership.75 When a patent 
held by a university or a small biotech company is licensed to a 
pharmaceutical, Big Pharma reaps huge rewards. Laws have evolved so that 
drug companies can lean upon other firms to perform a great deal of their 
R&D. This has enabled them to shift some of the creation and testing of new 
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drugs onto external operations.76 Drug companies license a third of their 
brands from universities or small biotech operations, reflecting the irony that 
very small ventures drive a large part of Big Pharma’s innovation.77 According 
to HBM Partners, a healthcare investing firm, a vast majority of drugs 
originate in smaller operations—64% of them in 2015.78  
Costs of bringing a drug to market are uncertain, vague, and often 
unverifiable. Gaining market approval for the development of a new medicine 
is an arduous process, easily taking over a decade. Some estimates suggest that 
bringing a drug to market costs in the neighborhood of $2.6 million, according 
to a study by the Tufts Center for the Study of Drug Development.79 To 
encourage drug development in the U.S., regulatory laws permit 
pharmaceutical firms to set their own pricing and provide protections that are 
tantamount to limiting free-market competition.80 Other countries set a limit on 
what firms can charge based on the benefit of each drug. In theory, it seems 
prudent to ensure that pharmaceuticals can recoup some of their losses, so they 
will continue to invest in risk-intensive choices that benefit those in need. 
Drugs with very small markets present particularly high investment risks. 
Some drugs do not make it to market. Once a drug is approved, determining a 
reasonable profit remains controversial.  
Part of the problem is the number of stakeholders in the system, including 
insurers, pharmacy benefit managers, pharmacies, and wholesalers, all of 
whom net profit from the sale of prescription drugs. While manufacturers bear 
the burden of drug production expenses they also keep the majority of the 
profit. To illustrate, of every $100 spent on prescription drugs by consumers 
(i.e., patients), $58 is received by the manufacturer, of which $17 is spent on 
drug production, $15 is kept as profit, and $26 is utilized for other 
expenditures, such as marketing and R&D.81 Total net profit on a $100 
expenditure is $23, of which $15 goes to manufacturers, $3 to insurers, $3 to 
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pharmacies, and $2 to pharmacy benefit managers.82 While these figures vary, 
depending on whether the purchased drugs are generic or branded, only 17% of 
the cost is estimated to fund drug development, while 23% of the total 
purchase price is absorbed by stakeholders as profit.83  
The unintended consequence of the money flow throughout the distribution 
system and supply chain is that pharmaceutical firms can corner the market on 
a particular drug and then drive up the price. It is arguable that the prices drug 
companies charge could be cut dramatically without threatening future 
investments in R&D or eroding future profits. Research and development is a 
relatively small part of Big Pharma’s budget, especially in comparison to the 
amount spent on sales and marketing. For every dollar spent on R&D, nineteen 
dollars go to marketing.84 Said differently, 9 out of 10 of the biggest 
pharmaceutical companies actually spend more on advertising than on R&D, 
according to The Washington Post.85 Sixteen drugs accounted for more than 
$100 million each in spending last year, with the most advertised drug being 
arthritis treatment Humira, at $357 million, according to the health news site 
Stat.86 The average stock return over the last decade for the 10 biggest 
pharmaceutical companies based on 2015 sales is 88%.87 This statistic is 
skewed, impacted by the unseemly returns of over 480% during the period for 
Gilead.88  
Given its mega-profits, Big Pharma has become known for its ability to 
wield political and social influence over its stakeholders, including the federal 
government and its agencies, healthcare systems, insurance firms, medical 
practitioners and administrators, hospitals, and consumers. Big Pharma has 
become one of the most profitable industries in the U.S., with 25-30% net 
margin profits (2016), rivaled largely by accounting, legal, and investment 
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services, along with leasing operations and dentists (in 2017).89 The industry 
has so much power that it has actually shaped how Western medicine and its 
citizens think about their health and well-being. Pharmaceutical companies 
strategically produce what increases earnings for their shareholders. But when 
the zeal for profit becomes an overriding goal, the interests of non-shareholder 
stakeholders are ignored, as depicted in this 2015 email from Martin Shkreli, 
former CEO of Turing Pharmaceuticals, maker of Daraprim: 
$1bn here we come. I think it will be huge. We raised the price from 
$1,700 per bottle to $75,000. So 5,000 paying bottles at the new price 
is $375,000,000 . . . almost all of it is profit and I think we will get 3 
years of that or more. Should be a very handsome investment for all 
of us. Let’s all cross our fingers that the estimates are accurate.90  
Reports about how Turing acquired the full rights to a 60-year-old generic 
drug and then promptly raised its price 5000% outline how Shkreli’s bold 
projections complemented his strategy.91 The drug treats toxoplasmosis, a 
parasitic infection that is particularly perilous for HIV/AIDS patients. Turing’s 
documents were made public when participants on the House Government 
Reform and Oversight Committee investigated citizen outrage. Their inquiry 
confirmed the stark and grotesque reality: Turing had raised the price of 
Daraprim exorbitantly because it could do so—legally. In addition to windfall 
profits, the company reaped stakeholder backlash that forced Shkreli out. 
Amidst protests and investigations, fraud charges were brought against Shkreli 
and he was sentenced to a 7-year prison sentence in 2018.92 His expulsion, 
however, provided no relief to patients in desperate need of the drug.  
Unfortunately, such unseemly pricing strategies are not confined to one 
rouge greedy executive or a few unethical firms. Pricing decisions are 
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commonly based on the desire to maximize profits. For example, in early 2015 
Valeant Pharmaceuticals purchased two heart medications. Taking sole 
ownership, the company subsequently hiked prices by 525% and 212%, 
respectively.93  
In just one year, Valeant garnered $351 million in profits from these two 
products.94 But this success was short lived. After the U.S. Attorney’s offices 
subpoenaed the company, its stock price plunged. In another case, Mylan, 
maker of the EpiPen emergency remedy for anaphylaxis, paid nearly half a 
billion dollars to settle a Justice Department complaint for misclassifying the 
drug under Medicaid, while separately facing other legal  
complaints for overcharging consumers.95 
Industry professionals argue, however, that the market for medicines is 
unique. Both Turing and Valeant trade in medicines for uncommon illnesses, 
so-called orphan drugs (i.e., a small user base for medicines that treat rare 
diseases/disorders). Because so few patients need these drugs, there is little 
incentive for others to produce them and little or no competition. Leveraging 
this power, one Turing PowerPoint presentation strategically underscored the 
firm’s desire to control the market:  
 Drugs are typically nondiscretionary and consumers are relatively 
price-insensitive.  
 Typically, there is an inverse correlation between prevalence of a 
disease and the annual cost of treatment. 
 Exclusivity (closed distribution) creates a barrier and pricing 
power.96 
Turing’s internal strategy emphasized hiding costs from patients and 
avoiding fights with HIV/AIDs advocates and hospitals. But the firms that 
make headlines are not the only ones raising their prices; prescription 
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medication prices have been rising faster than inflation for years.97 Even the 
prices of generic drugs, which are supposed to provide consumers with less 
expensive options, have climbed: 30% profit in 2017 (i.e., generic drugs are 
now being priced to benefit shareholders over stakeholders).98 Big Pharma 
maintains that their motives are to produce additional income to advance the 
science of treatment, funding not only R&D but also patient access programs 
that dispense free or low-cost medicines to the uninsured and reduced co-
payments for certain populations. Valeant instituted patient access programs 
after receiving complaints about its prices. Although a few consumers benefit 
from these programs, the vast majority are hit hard by the high price of 
medication. 
Big Pharma has been involved in numerous billion-dollar lawsuits (see 
Table 2). In recent years, pharmaceutical companies have agreed to pay over 
$13 billion to resolve U.S. Department of Justice allegations of fraudulent 
marketing practices, including the promotion of medicines for uses that were 
not approved by the FDA.99 Cases typically involve misbranding and off-label 
marketing, giving kickbacks to physicians for prescribing and/or 
recommending drugs, and strategically aligning with generic companies as a 
means to keep the overall cost of drugs higher than their justified benefits.100 
Increases in the size and number of these cases contributes to the concern that 
the government itself has been complicit in the illicit behavior.101 
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Table 2. Major Settlements between Big Pharma and the U.S. Department of 
Justice (2009-13)102 
 
Company Name Drug Names Settlement Date 
GlaxoSmithKline Paxil, Wellbutrin $3 billion 2012 
Pfizer Bextra $2.3 billion 2009 
Johnson & Johnson Risperdal, Invega, 
Natrecor 
$2.2 billion 2013 
Abbott Laboratories Depakote $1.5 billion 2012 
Eli Lilly Zyprexa $1.4 billion 2009 
Amgen Aranesp $762 million 2012 
Sanofi-Aventis Hyalgan $109 million 2012 
Pharmaceutical companies are undeterred by fines, legal fees, and 
settlement payouts, which they seem to view as costs of doing business. The 
reality is that consumers ultimately pay for government programs through their 
tax dollars. Cost increases also contribute to higher insurance premiums, 
higher deductibles, and decreased coverage. The U.S. is the only major market 
where pharmaceutical pricing remains unregulated. Mahmud Hassan, director 
of Rutgers Business School’s pharmaceutical management program, says that 
stakeholders in the U.S.—patients, health insurers, and the government—pay 
more for their prescribed medicines than those in countries with national health 
programs, and sometimes double.103  
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nations pay for drugs, UPI (Aug. 23, 2016), http://www.upi.com/Health_News/2016/08/23/Americans-pay-
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IV. THE MEDICAL COMMUNITY 
Doctors, scientists, research organizations, medical journals, teaching 
hospitals, and university medical schools all accept money from the 
pharmaceutical industry. Medical researchers sometimes coauthor articles in 
concert with Big Pharma or receive funds for ghostwriting information that 
reflects certain results that may ultimately be published in medical journals. 
Research conducted by scientists associated with pharmaceutical firms has 
been used to promote (directly or indirectly) many drugs—including 
antidepressants Paxil and Zoloft, anti-epilepsy drug Neurontin, painkiller 
Vioxx, and recalled weight loss drug Fen-Phen. It is common practice for a 
pharmaceutical firm to pay a medical reviewer to write a comprehensive 
assessment of a new drug for a medical journal. Accounts of slanted research 
have appeared in medical journals, despite claims by authors of their unbiased 
scientific evaluation, separate from any financial ties to the industry. For 
example, the disclosure that in 1967 the sugar industry paid Harvard scientists 
to obscure a link between sugar and heart disease.104 An unintended 
consequence of this misleading information has been decades of research 
examining the effects of saturated fat—rather than sugar.105 Researchers say 
that this thwarted a more thorough investigation, which has likely contributed 
to an increase in the rate of heart disease in the U.S.106 
A former editor of the British Medical Journal describes how the 
pharmaceutical industry can cleverly use medical journals to their own 
advantage.107 Most, including the Journal of the American Medical 
Association, benefit from advertising dollars from Big Pharma. Drug 
companies also sponsor clinical trials that researchers are paid to administer. 
Academics and scientists conduct the research, collecting data and preparing 
and analyzing the findings. Nevertheless, sponsors often keep the data, prepare 
additional analyses, and report what supports their own agenda. Drug 
 
 104 Cristin E. Kearns, et al., Sugar Industry Influence on The Scientific Agenda of The National Institute 
of Dental Research’s 1971 National Caries Program: A Historical Analysis of Internal Documents, PLOS MED. 
12(3): e1001798 (2015). 
 105 Anahad O’Connor, How the sugar industry shifted the blame to fat, N.Y. TIMES (Sep. 12, 2016), 
http://www.nytimes.com/2016/09/13/well/eat/how-the-sugar-industry-shifted-blame-to-fat.html?_r=0.  
 106 American Heart Association, Added sugars add to your risk of dying from heart disease, AMERICAN 
HEART ASSOCIATION: HEALTHY LIVING (Sep. 16, 2016), http://www.heart.org/HEARTORG/HealthyLiving/
HealthyEating/Nutrition/Added-Sugars-Add-to-Your-Risk-of-Dying-from-Heart-Disease_UCM_460319_ 
Article.jsp#.V-6cISWQLX4.  
 107 Rosa Ahn, et al., Financial ties of principal investigators and randomized controlled trial outcomes: 
Cross sectional study, THE BRITISH MEDICAL JOURNAL 356 i6770 (2017). 
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companies may stage-manage drug trials, revealing the outcomes that put their 
products in the best light. 
Doctors in the U.S. are typically required to take accredited continuing 
medical education (CME) coursework. The pharmaceutical industry provides a 
substantial proportion of the annual costs of CME, using this platform as a 
means to market their products.108 Drug company representatives are key 
players within the U.S. healthcare delivery system, educating doctors so they 
can prescribe drugs appropriately. At the same time, pharmaceutical firms train 
their representatives to push the newest (often the most expensive) products.109 
As previously described, academic centers can receive royalties from Big 
Pharma on any drug or technology they help to create and patent, often 
underwritten with government funds. Columbia University, for example, 
received nearly $790 million from licensing agreements with biotech and 
pharmaceutical companies during the 17-year life of its medical school’s 
patent on a method for synthesizing certain biological products.110  
In the U.S., there is one pharmaceutical sales representative for every 2.5 
office-based physicians.111 In recent years, however, some facilities have 
imposed a closed-door policy, reducing this practice (by some accounts to 
1:5).112 In some cases, physicians may welcome salespeople because they 
provide free samples, which they can then use for their patients. Big Pharma 
claims that this practice improves patient care, fosters appropriate medication 
use, and helps millions of financially struggling patients. But scholars have 
countered that “sampling” is not effective in improving drug access for the 
indigent, does not promote rational drug use, and raises the cost of care.113  
 
 108 JEROME P. KASSIRER, M.D , ON THE TAKE: HOW MEDICINE’S COMPLICITY WITH BIG BUSINESS CAN 
ENDANGER YOUR HEALTH (Oxford University Press, 2005); see also Amanda L. Connors, Big bad pharma: An 
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 111 Adriane Fugh-Berman & Shahram Ahari, Following the script: How drug reps make friends and 
influence doctors, PLOS MED (2007), http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed. 
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Also troubling is that healthcare professionals are continuously encouraged 
to resolve patients’ concerns by prescribing medications. Given the pressure to 
see more patients in less time, the system pushes physicians to provide quick 
prescription-driven remedies. As a result of DTCPAs, consumers’ can be 
psychologically manipulated and there is a greater likelihood for doctors to 
inappropriately prescribe certain drugs.114 Pharmaceutical companies also 
sponsor symposia and medical conventions, offering medical practitioners 
opportunities to extend their education. These events often include free travel 
and other benefits, making it difficult to be anything but favorably inclined 
towards the sponsoring firms that help subsidize them. In medical schools, 
preceptors, teachers, department chairs, and deans may sit on drug companies’ 
boards of directors. Money from Big Pharma also supports educational 
programming within many medical schools and teaching hospitals. Company 
reps can gain access to doctors in these settings and promote their wares.115 
This serves to reinforce a drug-intensive style of practice.  
V. MOVING FORWARD 
It has been a decade since Hirsch called for pharmaceutical firms to adopt a 
system of corporate social responsibility.116 He urged leaders to recognize and 
protect stakeholders, prompting a shift from the bottom line model to one that 
inculcates ethics and human rights. But years later, Big Pharma is still largely 
driven by providing fiduciary gains to shareholders and corporate executives. 
Its profound focus on self-interest places in question how much of what it does 
actually benefits society. Over the past several decades, the pharmaceutical 
industry has generally become a marketing machine to sell drugs that generate 
the ultimate highest profit potential. As Big Pharma wields its power within the 
U.S. Congress, FDA, academic medical centers, and within the medical 
profession itself, patients are likely to find themselves confused, frustrated 
about options, and without recourse.  
More recently, consumers are now experiencing huge pricing variations for 
the exact same drugs. A study in April of 2018 by Consumer Reports suggests 
that pharmacies are now imposing their own price increases, without notice to 
consumers. In comparing what it would cost (retail cash prices for a one-month 
 
 114 Elizabeth C. Melby, The Psychological Manipulation of the Consumer-Patient Population Through 
Direct-to-Consumer Prescription Drug Advertising, 5 SCHOLAR 325 (2002). 
 115 MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES: HOW THEY DECEIVE US AND WHAT TO 
DO ABOUT IT (2004). 
 116 Hirsch, M. L. (2008). Side effects of corporate greed: Pharmaceutical companies need a dose of 
corporate social responsibility. Minn. JL Sci. & Tech., 9, 607. 
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supply of five commonly prescribed drugs, the range in prices was stunning. 
All five drugs were only $66 when purchased at the online pharmacy 
HealthWarehouse.com, $105 when purchased at Costco. The two highest-
priced national retailers—CVS and Rite Aid—had prices closer to $900 for the 
very same drugs.117 What adds to the distressing nature of this practice is that 
when a consumer uses their insurance, they may now be told that certain drugs 
are no longer covered by their insurance, and shocked to see what used to be 
$10 is now much more (in this cast $60) (first author personal experience at 
CVS, April 1, 2018). In fact, taking this exact same prescription to another 
drugstore that day (in this case, Walgreen’s), produced an approved co-pay 
amount of $10 (i.e., the insurance did cover it). This lack of transparency 
includes bizarre rationales by drugstores, based on whether or not they 
received a coupon for the drug, from the manufacturer. At this point, 
consumers literally have to shop around to find where their co-pays will be 
honored and to find the best prices for their prescriptions. This may include 
resorting to crossing borders, literally or via the Internet to procure cheaper 
medicine. In largess, it is typically considered to be illegal for citizens to 
import prescription drugs into the U.S. And the Food and Drug Administration 
says:  
Medicine bought from foreign sources, such as from Internet sellers, 
from businesses that offer to buy foreign medicine for you, or during 
trips outside the United States, may not be safe or effective. These 
medicines are illegal and may present health risks, and FDA cannot 
ensure the safety, efficacy and quality of medicine from these 
sources. FDA cannot help consumers who have problems with 
medicine obtained from outside U.S. regulation and oversight.118 
As consumers continue to navigate this opaque and continuously changing 
market, the cost and complexities of drug discovery continue to increase. This 
is causing Big Pharma to shift from the development of medicine that targets 
short-course therapies for acute diseases to the long-term treatment of chronic 
conditions. And, despite a growing clinical need, there is a disturbing lack of 
investment in producing novel antibacterial agents. Drug options for treatment 
of infections have become increasingly limited, as antimicrobial resistance 
becomes increasingly robust. Generic antibiotics are in short supply, and the 
development of new antibiotics has been severely curtailed. Only four large 
 
 117 Lisa L. Gill, Shop Around for Lower Drug Price, Consumer Report (Apr. 5, 2018), 
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pharmaceutical companies with antibiotic research programs remained in 
existence in 2002. As reported by Pew Research in 2016: 
New discoveries dropped precipitously from the 1980s onward. As a 
result, the development of antibiotics has declined, with new FDA 
approvals for these drugs falling from 29 during the 1980s to nine in 
the first decade of the 2000s. All antibiotics approved for use in 
patients today are derived from a limited number of types, or classes, 
of antibiotics that were discovered by the mid-1980s. This is even 
more concerning than the decline of drug approvals because 
resistance to one antibiotic often leads to resistance to multiple 
antibiotics within the same class. Faced with poor discovery 
prospects and diminishing returns on investment, major drug 
companies have cut back or pulled out of antibiotic research 
altogether. This has left much of the remaining discovery work to 
small, “pre-revenue” companies with no products on the market and 
limited budgets and R&D capacity. Most industry antibiotic 
development programs are primarily focused on modifying existing 
classes of drugs discovered decades ago to circumvent bacterial 
resistance and better target difficult-to-treat infections. Though 
essential, such incremental advances are not likely to meet the 
looming public health challenge of antibiotic resistance in the long 
term.119 
Pharmaceutical companies face a paradox wherein federal agencies call for 
antibiotic development even as other federal agencies enact policies limiting 
the appeal of that very development.120 
Critics from the medical stakeholder community claim there is insufficient 
science guiding pharmaceutical business decisions and that financial incentives 
go in the wrong direction. Big Pharma wants consumers to take a pill every 
day for the rest of their lives. Therefore, they invest in new forms of birth 
control, cholesterol blockers, and antidepressants that dominate the market. 
Meanwhile, vaccines have become scarce. Big Pharma and its university 
partners have been charged with paying little attention to salient issues of 
public health, and focusing instead on products expected to maximize profits. 
Critics underscore how Big Pharma has grossly subordinated patient needs in 
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favor of its own investment returns.121 Allen Frances, Chair of the DSM-IV 
Task Force, warns that the gradual mislabeling of everyday problems as illness 
has toxic implications for individuals and society: stigmatizing people, 
introducing them to potentially harmful medications, misallocating medical 
resources, and draining the budgets of families and the nation. Wellness has 
been shifted away from our own naturally resilient and self-healing capacity, 
into the hands of Big Pharma, who reap multi-billion-dollar profits at citizens’ 
expense.122 
Big Pharma presents a disturbing ironic reality: the industry offers life-
saving health benefits, and yet remains one of the least trusted. The reality is 
that “some of the largest drug companies in the world—the one’s that we rely 
on for life saving treatments—are convicted criminals.”123 Are regulators 
enablers? Or, perhaps worse still, are they complicit in questionable or 
ethically unsound activities as a result of being driven by self-serving motives? 
Working to untie and address this Gordian knot of interrelated profiteering and 
motivated special interests will require increased stakeholder engagement and 
government activism. U.S. Senator Bernie Sanders (I-VT) asserts that “people 
must be prepared to stand up to powerful special interests like the 
pharmaceutical industry and like Wall Street.”124 Before taking office, 
President Donald Trump said the pharmaceutical industry was “getting away 
with murder,” and vowed to do something about it.125 The reality to date, 
however, is that Big Pharma has the power to continue to dictate the pricing of 
drugs in the U.S., where our legal platform continues to offer incentives for 
firms to extract exorbitant prices. Traditional common law remedies have not 
resulted in deterrence.126 
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Despite public knowledge of Big Pharma’s self-serving practices, 
pharmaceutical companies claim that their mission is to benefit people. 
Reformers call for restructuring the industry itself, so that it remains grounded 
in science but is genuinely motivated to provide safe and effective drugs for 
the public. Accomplishing this aim will require protracted and sustained citizen 
and stakeholder engagement, demonstrated via a determined commitment to 
prompt reflection, informed dialogue, and bipartisan reform. To create 
systemic change, fresh ideas need to be explored. One plan for tackling the 
expensive limited access to drugs has emerged from the medical community. 
The idea is for the U.S. federal government to buy pharmaceutical firms 
outright, rather than buying the drugs themselves.127  
For example, according to the Center for Disease Control and Prevention, 
Hepatitis C kills more Americans than any other infectious disease and often 
leads to a need for liver transplants.128 Gilead Sciences Inc. makes Sovaldi and 
Harvoni, the two drugs that can swiftly cure this disease, but sells them at 
prices so high that few can afford them (a 12-week course is $84,000).129 
States restrict their use, telling patients they are not sick enough to justify the 
cost. The drugs consistently eradicate the virus, which has infected an 
estimated 2.7 to 3.3 million people in America.130 Buying the company instead 
of the drugs would cut the cost of treatment by almost two-thirds. The 
government could then sell the firm itself, but sustain the drug rights. Doing so 
would cut the cost of treatment, stop the disease from spreading, and reduce 
the number of liver transplants needed.  
The idea of having the government purchase corporate shares at full price 
on the open market may seem far-fetched. But it represents the kind of 
transformational thinking that might help to promote deep change. Experts say 
that if the federal government treated illnesses as public health issues, rather 
than as Medicaid budget problems, innovative ideas like this one would be 
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more likely to emerge.131 They argue that the government needs to focus 
explicitly on curing and saving patients, and to move away from reinforcing 
practices such as prescription-based care and drug dependency, which benefit 
the industry but harm citizens. Manufacturers and suppliers need to co-create 
stakeholder codes of conduct that reduce or eliminate DTCPA and reflect 
increasing efforts to support and enhance public awareness of disease 
prevention and management. Executives leading Big Pharma firms must be 
held accountable; liable for the misconduct they participate in, enable, or turn a 
blind eye toward. Prosecutors need to be able to exact penalties that are potent 
enough to affect corporate behavior, such as fines that involve garnishing 15% 
of a firm’s annual profits and executive compensation and benefits. Some 
suggest that Big Pharma be regulated like public utilities.132 If the government 
regulated drug pricing, as it does for electricity, it would likely prompt 
competition between companies and drive prices lower, benefiting all, 
including government programs. 
The convergence of IT and healthcare is another path that might prompt a 
shift in the Big Pharma model. Big data, apps, and mobile health are starting to 
transform healthcare and diagnostics in a significant way, with Apple and 
Google acting as steadfast disruptive catalysts. Medicines paired with 
companion diagnostics may be an increasingly leveraged strategy to gain 
market access. At present, AstraZeneca, Roche, Novartis and Sanofi are 
progressing as much as 60–80% of their clinical portfolios with companion 
diagnostics.133 In the era of personalized and precision medicines, this strategy 
will likely translate into medicines accompanied with apps or wearable devices 
that help patients monitor key parameters and manage their diseases. How big 
pharma adapts to this ‘beyond-the-pill’ model will be an interesting 
development during the next decade.134 
In broader terms, academic institutions need to educate the next generation 
of business leaders to view social responsibility and governance as key 
components in the calculation of value and profit. It is not enough to increase 
the value of corporate stock in the short term. Firms must incorporate a 
stakeholder perspective, accompanied by a longer-term profit horizon. Perhaps 
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policymakers can leverage insights from business protocols like “B Corp,” 
where certification requires the ability of a firm to meet rigorous stances of 
social and environmental performance, accountability, and transparency.135 
Big Pharma, affecting the health and welfare of every citizen, is at the 
intersection of business and society. Policy and lawmakers who are free from 
the influence of lobbying forces must help corral Big Pharma, toward 
redirecting a reasonable portion of their profits to benefit consumers. This is 
both possible and feasible via legislation that imposes stricter regulations on 
DTCPA and limits drug patent extensions, as well as the reevaluation of the 
learned intermediary doctrine by the judicial system.136 How this industry 
moves forward presents one of the biggest ethical challenges of the 21st 
century, seeking a balance between capitalism and the corporation’s duty to its 
share- and stakeholder constituents. 
 
 
 135 Certified B Corporation, What Is a B Corp?, https://www.bcorporation.net/what-are-b-corps (last 
visited Apr. 23, 2018). 
 136 Elizabeth C. Melby, Comment: The Psychological Manipulation of the Consumer-patient Population 
through Direct-to-consumer Prescription Drug Advertising, 5 SCHOLAR 325, 353 (2003).  
